Premium
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs for Substance Abuse
Author(s) -
King Jennifer R.,
Me Rajeev M.
Publication year - 2017
Publication title -
clinical pharmacology in drug development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 22
eISSN - 2160-7648
pISSN - 2160-763X
DOI - 10.1002/cpdd.327
Subject(s) - ombitasvir , dasabuvir , medicine , paritaprevir , ritonavir , regimen , raltegravir , atazanavir , hepatitis c , lamivudine , pharmacology , ribavirin , virology , viral load , hepatitis c virus , human immunodeficiency virus (hiv) , hepatitis b virus , virus , antiretroviral therapy
AbbVie's 3 direct‐acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Safe and efficacious antiviral regimens resulting in minimal to no drug–drug interactions (DDIs) with antiretrovirals are needed to ensure that patients coinfected with HCV and the human immunodeficiency virus (HIV) achieve 12‐week sustained virologic response rates similar to HCV‐monoinfected patients. Also, the prevalence of injection drug use history is high in both monoinfected and HIV/HCV‐coinfected patients. This review summarizes results from phase 1 DDI studies of the 3D regimen and antiretrovirals or drugs to treat substance abuse. Data suggest the 3D regimen is a viable option for HIV/HCV‐coinfected patients on antiretroviral therapy containing tenofovir/emtricitabine, abacavir/lamivudine, dolutegravir, raltegravir, or atazanavir. HCV‐infected patients receiving medications for substance abuse, particularly methadone or buprenorphine/naloxone, can also be treated with the 3D regimen.